PENERBITAN

LIMOSILACTOBACILLUS REUTERI DSM 17938-CONTAINING INFANT FORMULAS AND THE ASSOCIATIONS WITH GASTROINTESTINAL TOLERANCE: A CROSS-SECTIONAL OBSERVATIONAL STUDY

Author: Happy Tummy Consortium, Luca Lavalle, Nicolas Sauvageot, Colin Ivano Cercamondi, Ivana Jankovic, Delphine Egli, and Yvan Vandenplas

Date of publication: 19/01/2023

ACS
PEMBROLIZUMAB VERSUS PACLITAXEL FOR PREVIOUSLY TREATED ADVANCED GASTRIC OR GASTROESOPHAGEAL JUNCTION CANCER (KEYNOTE-063): A RANDOMIZED, OPEN-LABEL, PHASE 3 TRIAL IN ASIAN PATIENTS

Author: Hyun Cheol Chung MD, PhD, Yoon-Koo Kang MD, PhD, Zhendong Chen MD, Yuxian Bai MD, Wan Zamaniah Wan Ishak MD, Byoung Yong Shim MD, Young Lee Park MD, Dong-Hoe Koo MD, PhD, Jianwei Lu MD, Jianming Xu MD, Hong Jae Chon MD, Li-Yuan Bai MD, Shan Zeng MD, Ying Yuan MD, Yen-Yang Chen MD, Kangsheng Gu MD, Wen Yan Zhong PhD, Shu Kuang MD, Chie-Schin Shih MD, Shu-Kui Qin MD, PhD
Date of publication: 08/12/2021

NCBI
EFFICACY AND SAFETY OF THE ADDITION OF SITAGLIPTIN TO TREATMENT OF YOUTH WITH TYPE 2 DIABETES AND INADEQUATE GLYCEMIC CONTROL ON METFORMIN WITHOUT OR WITH INSULIN

Author: Muhammad Yazid Jalaludin, Asma Deeb, Philip Zeitler, Raymundo Garcia, Ron S Newfield, Yulia Samoilova, Carmen A Rosario, Naim Shehadeh, Chandan K Saha, Yilong Zhang, Martina Zilli, Lynn W Scherer, Raymond L H Lam, Gregory T Golm, Samuel S Engel, Keith D Kaufman, R Ravi Shankar
Date of publication: 14/11/2021

NCBI
A RANDOMIZED CLINICAL TRIAL OF THE EFFICACY AND SAFETY OF SITAGLIPTIN AS INITIAL ORAL THERAPY IN YOUTH WITH TYPE 2 DIABETES

Author: R Ravi Shankar, Philip Zeitler, Asma Deeb, Muhammad Yazid Jalaludin, Raymundo Garcia, Ron S Newfield, Yulia Samoilova, Carmen A Rosario, Naim Shehadeh, Chandan K Saha, Yilong Zhang, Martina Zilli, Lynn W Scherer, Raymond L H Lam, Gregory T Golm, Samuel S Engel, Keith D Kaufman
Date of publication: 14/11/2021

New-England-Journal-of-Medicine
LIRAGLUTIDE IN CHILDREN AND ADOLESCENTS WITH TYPE 2 DIABETES

Author: William V. Tamborlane, M.D., Margarita Barrientos-Pérez, M.M.S.C.I., Udi Fainberg, M.D., Helle Frimer-Larsen, M.Sc., Mona Hafez, M.D., Paula M. Hale, M.D., Muhammad Y. Jalaludin, M.D., Margarita Kovarenko, M.D., Ingrid Libman, M.D., Jane L. Lynch, M.D., Paturi Rao, Ph.D., Naim Shehadeh, M.D., et al., for the Ellipse Trial Investigators*
Date of publication: 15/08/2019

elsevier
ALTERED CIRCULATING CONCENTRATIONS OF ACTIVE GLUCAGON-LIKE PEPTIDE (GLP-1) AND DIPEPTIDYL PEPTIDASE 4 (DPP4) IN OBESE SUBJECTS AND THEIR ASSOCIATION WITH INSULIN RESISTANCE

Author: Radwan H.Ahmed,Hasniza Zaman Huri, Sekaran Muniandy, Zaid Al-Hamodi, Boshra Al-absi, Abdulsamad Alsalahi, Muhammad FM Razif
Date of publication: 10/09/2017

elsevier
P 019 – ALTERATIONS OF CULTURED MYOTUBES AND FASTING PLASMA METABOLITE PROFILES RELATED TO MITOCHONDRIAL DYSFUNCTION IN TYPE 2 DIABETES SUBJECTS

Author: Mohamad Hafizi AbuBakar,HasnizaZaman Huri,Nany Hairunisa
Date of publication: 06/07/2017

NCBI
STATIN THERAPY PRESCRIBING FOR PATIENTS WITH TYPE 2 DIABETES MELLITUS: A REVIEW OF CURRENT EVIDENCE AND CHALLENGES

Author: Mohamed Hassan Elnaem,1 Mohamad Haniki Nik Mohamed,1 Hasniza Zaman Huri,2 Shah M. Azarisman,3 and Ramadan Mohamed Elkalmi4
Date of publication: 01/06/2017

dove-press
APOPTOTIC INDUCTION AND INHIBITION OF NF-ΚB SIGNALING PATHWAY IN HUMAN PROSTATIC CANCER PC3 CELLS BY NATURAL COMPOUND 2,2′-OXYBIS (4-ALLYL-1-METHOXYBENZENE), BISEUGENOL B, FROM LITSEA COSTALIS: AN IN VITRO STUDY

Author: Abbaspour Babaei M, Zaman Huri H, Kamalidehghan B, Yeap SK, Ahmadipour F
Date of publication: 10/01/2017

dove-press
RECEPTOR TYROSINE KINASE (C-KIT) INHIBITORS: A POTENTIAL THERAPEUTIC TARGET IN CANCER CELLS

Author: Maryam Abbaspour Babaei,1 Behnam Kamalidehghan,2,3 Mohammad Saleem,4–6 Hasniza Zaman Huri,1,7 Fatemeh Ahmadipour1
Date of publication: 01/08/2016

future-medicine
CLINICAL AND GENETIC PREDICTORS OF DIPEPTIDYL PEPTIDASE-4 INHIBITOR TREATMENT RESPONSE IN TYPE 2 DIABETES MELLITUS

Author: Jazlina Liza Jamaluddin, Hasniza Zaman Huri & Shireene Ratna Vethakkan
Date of publication: 01/06/2016

future-medicine
GENETIC POLYMORPHISMS ASSOCIATED WITH OVERWEIGHT AND OBESITY IN UNCONTROLLED TYPE 2 DIABETES MELLITUS

Author: Nor Bahirah Kasim, Hasniza Zaman Huri, Shireene Ratna Vethakkan, Luqman Ibrahim & Bashar Mudhaffar Abdullah
Date of publication: 21/03/2016

nature
GENETIC MARKERS PREDICTING SULPHONYLUREA TREATMENT OUTCOMES IN TYPE 2 DIABETES PATIENTS: CURRENT EVIDENCE AND CHALLENGES FOR CLINICAL IMPLEMENTATION

Author: Hasniza Zaman Huri, N K Loganadan, , S R Vethakkan & Z Hussein
Date of publication: 26/01/2016

science-alert
A REVIEW ON BIOLOGICALLY ACTIVE N-MYRISTOYLATED HIV-1 NEF PROTEIN

Author: Krisna Veni Balakrishnan, Bashar Mudhaffar Abdullah, Hasniza Zaman Huri, Nany Hairunisa and Narazah Mohd Yusoff
Date of publication: 29/10/2015

science-alert
ANTITUMOR ACTIVITY FOR GOLD (III) COMPLEX BY HIGH CONTENT SCREENING TECHNIQUE (HCS) AND CELL VIABILITY ASSAY

Author: Firas Hassan, Ayah Abdul Hameed, Ahemd Alshanon, Bashar Mudhaffar Abdullah, Hasniza Zaman Huri, Nany Hairunisa and Emad Yousif
Date of publication: 29/10/2015

texas
UNRUPTURED SINUS OF VALSALVA ANEURYSM WITH RIGHT VENTRICULAR OUTFLOW TRACT OBSTRUCTION AND SUPRACRISTAL VENTRICULAR SEPTAL DEFECT: A RARE CASE

Author: Ganiga Srinivasaiah Sridhar, Muhammad Athar Sadiq, Wan Azman Wan Ahmad, Chitra Supuramania, Timothy Watson, Imran Zainal Abidin, and Kok Han Chee
Date of publication: 01/10/2015

logoS
UNDER-RECOGNISED PERTUSSIS IN ADULTS FROM ASIAN COUNTRIES: A CROSS-SECTIONAL SEROPREVALENCE STUDY IN MALAYSIA, TAIWAN AND THAILAND. EPIDEMIOLOGY AND INFECTION. 2015 (IN PRESS)
biomed
A RANDOMISED TRIAL TO EVALUATE THE IMMUNOGENICITY, REACTOGENICITY, AND SAFETY OF THE 10-VALENT PNEUMOCOCCAL NON-TYPEABLE HAEMOPHILUS INFLUENZAE PROTEIN D CONJUGATE VACCINE (PHID-CV) CO-ADMINISTERED WITH ROUTINE CHILDHOOD VACCINES IN SINGAPORE AND MALAYSIA

Author: Prof Dr Koh Mia Tuang(Department of Paediatrics-University of Malaya Medical Centre)
Date of publication: 02/10/2014

elsevier
SAFETY AND IMMUNOGENICITY OF A TETRAVALENT DENGUE VACCINE IN HEALTHY CHILDREN AGED 2–11 YEARS IN MALAYSIA: A RANDOMIZED,PLACEBO-CONTROLLED, PHASE III STUDY

Author: Prof. Dr. Koh Mia Tuang (Department of Paediatrics-University of Malaya Medical Centre)
Date of publication: 02/12/2013

WOL_Stacked_k.jpg
IMPACT OF LEPTIN RECEPTOR GENE VARIANTS ON RISK OF NON-ALCOHOLIC FATTY LIVER DISEASE AND ITS INTERACTION WITH ADIPONUTRIN GENE

Author: Shamsul Mohd Zain,Zahurin Mohamed, Sanjiv Mahadeva, Phaik-Leng Cheah, Sanjay Rampal, Kin-Fah Chin, Anis Shafina Mahfudz, Roma Choudhury Basu, Hwa-Li Tan, Rosmawati Mohamed
Date of publication: 25/04/2013

plos-one
SUSCEPTIBILITY AND GENE INTERACTION STUDY OF THE ANGIOTENSIN II TYPE 1 RECEPTOR (AGTR1) GENE POLYMORPHISMS WITH NON-ALCOHOLIC FATTY LIVER DISEASE IN A MULTI-ETHNIC POPULATION

Author: Shamsul Mohd Zain,Zahurin Mohamed, Sanjiv Mahadeva, Sanjay Rampal, Roma Choudhury Basu, Phaik-Leng Cheah, Agus Salim, Rosmawati Mohamed
Date of publication: 06/03/2013

spinger
A MULTI-ETHNIC STUDY OF A PNPLA3 GENE VARIANT AND ITS ASSOCIATION WITH DISEASE SEVERITY IN NON-ALCOHOLIC FATTY LIVER DISEASE

Author: Shamsul Mohd Zain,Rosmawati Mohamed,Sanjiv Mahadeva,Phaik Leng Cheah,Sanjay Rampal,Roma Choudhury Basu,Zahurin Mohamed
Date of publication: 19/01/2012

biomed
A PHASE III, MULTI-CENTRE, DOUBLE-BLIND, RANDOMISED STUDY TO ASSESS THE NON-INFERIORITY OF A COMMERCIAL LOT OF GLAXOSMITHKLINE (GSK) BIOLOGICALS’ 10-VALENT PNEUMOCOCCAL CONJUGATE (10PN-PD-DIT) VACCINE COMPARED TO A CLINICAL PHASE III VACCINE LOT, WHEN GIVEN AS A THREE-DOSE PRIMARY IMMUNIZATION COURSE.

Author: Fong Seng Lim, Mia Tuang Koh, Kah Kee Tan, Poh Chong Chan, Chia Yin Chong, Yeo Wee Shung Yehudi, Yee Leong Teoh, Fakrudeen Shafi, Marjan Hezareh, Kristien Swinnen and Dorota Borys

Date of publication: 2 October 2014

Scroll to Top
Room Booking
Insurance Application
eServices
iPesakit

cic ummc

cic.ummc

cicummc

clinical investigation centre

Let's Connect !